• Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

  • Jun 24 2024
  • Length: 1 hr and 23 mins
  • Podcast

Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC  By  cover art

Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

  • Summary

  • This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.

    Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Cholangiocarcinoma Foundation, and the Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

    Disclosure information is available at the beginning of the video presentation.

    Show more Show less
activate_primeday_promo_in_buybox_DT

What listeners say about Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.